Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.
Shandong Xinhua Pharmaceutical said its wholly owned unit, Shandong Zibo Xincat Pharmaceutical, has obtained National Medical Products Administration approval and drug registration certificates for two specifications of its Saxagliptin and Metformin Hydrochloride sustained-release tablets. The combination diabetes therapy, classified as a Class 4 chemical prescription drug for domestic production, strengthens the group’s product pipeline in chronic disease management and supports its competitive position in China’s expanding market for modern oral hypoglycemic agents.
The approved tablets contain fixed-dose combinations of saxagliptin and metformin in 5 mg/1000 mg and 2.5 mg/1000 mg strengths, with quality standards, labelling and production processes to follow the registered documentation. While no financial figures were disclosed, the regulatory clearance enables commercialisation of the product in China, potentially diversifying revenue streams for the group and reinforcing its subsidiary Xincat Pharmaceutical as an active player in high-value, differentiated generic formulations.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a PRC-based pharmaceutical manufacturer listed in Hong Kong, operating through subsidiaries such as Shandong Zibo Xincat Pharmaceutical. The group focuses on the development, production and domestic registration of chemical prescription drugs, targeting key therapeutic areas in the Chinese healthcare market.
Average Trading Volume: 1,133,891
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.16B
For detailed information about 0719 stock, go to TipRanks’ Stock Analysis page.